• hCDR1 peptide

hCDR1 peptide

Not For Human Use, Lab Use Only.

Cat.#: 319279

Size:
Optional Service: TFA RemovalWhat's this?

Special Price 161.4 USD

Availability: 1-2 weeks
- +

Add to cart to get an online quotation

Product Information

  • Product Name
    hCDR1 peptide
  • Documents
  • Sequence
    H-GYYWSWIRQPPGKGEEWIG-OH
  • Three letter code
    H-Gly-Tyr-Tyr-Trp-Ser-Trp-Ile-Arg-Gln-Pro-Pro-Gly-Lys-Gly-Glu-Glu-Trp-Ile-Gly-OH
  • Length (aa)
    19
  • Peptide Purity (HPLC)
    95.78%
  • Molecular Formula
    C111H149N27O28
  • Molecular Weight
    2309.52
  • Source
    Synthetic
  • Additional Information
    Peptide hCDR1 is a potential candidate for a novel specific treatment of systemic lupus erythematosus (SLE) patients. It is based on the complementarity determining region (CDR)1 of a human monoclonal anti-DNA autoantibody. The peptide has been shown to either prevent or treat an already established murine lupus in SLE-prone mice or in mice with induced experimental SLE. In the present study, it was tested for its therapeutic potential in a model of lupus in severe combined immunodeficient (SCID) mice engrafted with peripheral blood lymphocytes (PBL) of patients with SLE. The peptide was found to significantly down-regulate the levels of dsDNA-specific antibodies and ameliorate the clinical features manifested by proteinuria, human IgG complex deposits as well as deposits of murine complement C3.
  • Storage Guidelines
    Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual:Handling and Storage of Synthetic Peptides
  • References
    • Mauermann N, Sthoeger Z, Zinger H, Mozes E. Amelioration of lupus manifestations by a peptide based on the complementarity determining region 1 of an autoantibody in severe combined immunodeficient (SCID) mice engrafted with peripheral blood lymphocytes of systemic lupus erythematosus (SLE) patients. Clin Exp Immunol. 2004 Sep;137(3):513-20. doi: 10.1111/j.1365-2249.2004.02559.x. PMID: 15320900; PMCID: PMC1809128.
  • About TFA salt

    Trifluoroacetic acid (TFA) is a strong acid, which is commonly used to cleave synthesized peptides from solid-phase resins and is also used to improve HPLC performance in the peptide purification step. By default, custom peptides are delivered as lyophilized TFA salts, and can contain as much as 10-45% TFA.

    TFA in custom peptides can cause inexplicable discrepancies in subsequent assay data. For instance, TFA in nM concentrations has been shown to interfere with cellular assays, inhibiting cellular proliferation in some instances, and increasing cell viability in others . It has also been found to be an unintended allosteric modulator of the glycine receptor, GlyR.

    TFA Removal Service is recommended for:

    • Peptides that will be used in cellular assays
    • Peptides that will be used as APIs or in manufactured products
    • For hydrophilic peptides containing numerous basic residues

  • Molar Concentration Calculator

  • Dilution Calculator

  • Percent Concentration Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight

Peptide Services: NovoPro's peptide synthesis services include standard chemical peptide synthesis, peptide modification, peptide libraries, and recombinant peptide expression.

Standard Peptide Synthesis: NovoPro offers quality peptides at the most competitive prices in the industry, starting at $3.20 per amino acid. NovoPro provides PepBox – Automatic Quote Tool for online price calculation.

Peptide Modifications: NovoPro offers a wide range of peptide modification services including isotope labeling (2H, 15N, and 13C), multiple disulfide bonds, multiple phosphorylations, KLH, BSA, ovalbumin, amidation, acetylation, biotin, FITC, etc.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"